Clinical trials: Airflow Limitation
Respiratory (Chronic Obstructive Pulmonary Disease)
Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking.
- Trial name
- ALSAC (NCT07315958)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease), COPD
Dupilumab in Type 2-Inflamed COPD Across the Full Spectrum of Airflow Limitation: An Italian Multicentre Retrospective Cohort Study
This multicentre retrospective cohort study describes lung function and patient-reported outcomes in adults with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received add-on dupilumab in routine…
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD, Eosinophilia
- Trial name
- DUPICENTRO (NCT07788092)
- Testing
- Dupilumab
- Where
- 6 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera di Perugia
Asthma
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction.
- Trial name
- NCT01225913
- Testing
- fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Gelb, Arthur F., M.D.
Asthma
Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma
This study is designed to investigate whether the Phosphodiesterase 4 gene variability could be implicated in the salbutamol responsiveness in asthmatic children.
- Trial name
- PEGASE2 (NCT03592212)
- Testing
- Salbutamol
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation
- Trial name
- NCT01834885
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 29 sites in Austria, Germany
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation.
- Trial name
- NCT01860066
- Testing
- QVA149, fluticasone/salmeterol
- Where
- 31 sites in Argentina, Belgium and 3 more
- Sponsor
- Novartis Pharmaceuticals
Asthma
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction.
- Trial name
- NCT00576069
- Testing
- budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Gelb, Arthur F., M.D.